BriefTea
Every story in sixty words
Get the free app no ads · no paywallExplained in plain English
Survival rates for pancreatic cancer are among the lowest of all cancers, with around 10% of patients surviving five years or more. This grim statistic underscores why the trial results for daraxonrasib are so promising, showing tumours stopped growing in 90% of patients and even disappeared in some, offering a rare glimmer of hope.
Stories that explain this
New pill shows promise against pancreatic cancer.Related explainers
When will NHS patients get it? What is pancreatic cancer? What is aggressive cancer? How can AI cure cancer? Why does AI need so many chips? Can animals get cancer? What is bladder cancer? What is Blood Cancer UK?The full catalogue
Browse every card filed under M →We would like to count visits and see which links bring readers here. That means storing a random ID in your browser. No cookies, no ads, no profile. How it works.